Mary Kerr CEO NeRRe Therapeutics guest speaker at a recent Labiotech meeting in London

NeRRe Therapeutics is a clinical-stage biotech company focused on developing orvepitant, a potent and selective neurokinin-1 (NK1) receptor antagonist, to treat chronic, debilitating conditions driven by neural hypersensitivity, specifically those involving Substance P / NK1 receptor system dysfunction.

Useful LInks

Terms & Conditions
Cookie Notice
Privacy Policy
Clinical Trials Privacy Notice

linkedin
email

Close Menu

Home
About Us
What We Do
News
Contact

linkedin
email